tradingkey.logo

Weight management company WW's Q2 clinical revenue jumps 55% on semaglutide subscriptions

ReutersAug 11, 2025 11:19 AM


Overview

  • WW fiscal Q2 rev declines 6% yr/yr, Clinical rev grows 55%

  • Co completes strategic reorganization, reduces debt by $1.15 bln

  • Predecessor net income margin impacted by reorganization items in fiscal Q2


Outlook

  • Company projects full-year revenue of $685 mln to $700 mln

  • WW International expects adjusted EBITDA of $140 mln to $150 mln

  • Company cites ongoing challenges in behavioral business impacting revenue


Result Drivers

  • DEBT REDUCTION - Co completed strategic reorganization, reducing debt by $1.15 bln

  • CLINICAL GROWTH - Clinical revenues rose 55% yr/yr, driven by compounded semaglutide subscriptions

  • BEHAVIORAL CHALLENGES - Revenue decline attributed to ongoing headwinds in behavioral business


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

$189 mln

Q2 Net Income

$1.19 bln

Press Release: ID:nGNX3mWcLB

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI